| Current Price | $10.57 | Mkt Cap | $369.5M |
|---|---|---|---|
| Open | $10.38 | P/E Ratio | 0.00 |
| Prev. Close | $10.57 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.98 - $10.99 | Volume | 2,297,434 |
| 52-Wk Range | $1.63 - $12.99 | Avg. Daily Vol. | 2,315,676 |
A biopharmaceutical company that develops novel drugs for pain management and oncology.
| Current Price | $10.57 | Mkt Cap | $369.5M |
|---|---|---|---|
| Open | $10.38 | P/E Ratio | 0.00 |
| Prev. Close | $10.57 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $9.98 - $10.99 | Volume | 2,297,434 |
| 52-Wk Range | $1.63 - $12.99 | Avg. Daily Vol. | 2,315,676 |
The best Bull and Bear pitches based on recency and number of recommendations.
Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. As of December 31, 2009, the Company had four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a radio-labeled monoclonal antibody to treat… More
My 5 year old son just asked “what if we put a slice of turkey in the DVD player and it played a movie about the turkey’s whole life” and none of the parenting books I’ve read have prepared me for this question.
Read the most recent pitches from players about SAVA.
Recs
capptten
(< 20)
Submitted: 11/30/2020 8:05:16 PM :
Start Price:
$7.66
NASDAQ:SAVA Score:
+35.22
This is a high risk high reward stock. The company has changed the name to Cassava Science. The have completed a stage 2 study and raised and additional 75 million to bring cash up to about 94 million. This will allow them to do a stage 3 study which they will be meeting the FDA in January. The stage 2 showed improved many improved biomarkers and there were some stories of caregivers noticing improvement in some patients behaviors. All of this information is readily available. The company decided to raise the money to complete more studies than sell the at a discounted price. If this study goes well most feel that this company would be bought out in excess of $100 per share. I encourage you to read and do your own DD.
Recs
OklaBoston
(55.67)
Submitted: 9/6/2019 4:21:04 PM :
Start Price:
$9.45
NASDAQ:SAVA Score:
-3.50
SAVA bottoming out at less than 1/5 of it's 2 year high.
Recs
TerryHogan
(99.81)
Submitted: 10/12/2018 1:41:05 AM :
Start Price:
$1.36
NASDAQ:SAVA Score:
-641.46
I generally like to look at cash flow statements before making a decision. But there's not a whole lot to be gained from studying these. Zero revenue. Red Thumb.
Find the members with the highest scoring picks in SAVA.
medeaschild (< 20) Score: +1,230.29
The Score Leader is the player with the highest score across all their picks in SAVA.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| medeaschild | < 20 | 12/26/2018 |
|
NS | $0.76 | +1,289.51% | +59.22% | +1,230.29 | 0 Comment | |
| marcet | 73.65 | 3/2/2009 |
|
3W | $18.82 | -43.85% | +427.25% | +471.10 | 0 Comment | |
| foolrrrrrrrrrr | 46.59 | 11/13/2008 |
|
1Y | $37.61 | -71.89% | +356.12% | +428.02 | 0 Comment | |
| hackerbobZ | < 20 | 3/23/2009 |
|
5Y | $17.65 | -40.12% | +382.12% | +422.25 | 0 Comment | |
| Dennyf10 | 59.21 |
|
|
1Y | $35.72 | -70.41% | +321.06% | +391.48 | 0 Comment | |
| deemonfather42 | < 20 | 7/6/2009 |
|
3W | $22.42 | -52.86% | +322.13% | +374.98 | 0 Comment | |
| kozmo66 | < 20 | 9/22/2008 |
|
3M | $38.69 | -72.68% | +209.38% | +282.06 | 0 Comment | |
| martijnvanwerde | 95.82 | 10/19/2006 |
|
3M | $35.60 | -70.31% | +192.48% | +262.78 | 0 Comment | |
| TheDecider | 33.79 | 1/27/2011 |
|
5Y | $34.90 | -69.72% | +189.33% | +259.05 | 0 Comment | |
| Whereismymony | < 20 | 12/8/2006 |
|
3M | $36.27 | -70.86% | +182.61% | +253.47 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
